Potential Impact of Regorafenib in Patients With HCC

Video
Conference|ASCO Annual Meeting

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential impact that regorafenib (Stivarga) could have on the treatment landscape of hepatocellular carcinoma (HCC).

Recent Videos
Related Content
Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Kristie L. Kahl
November 15th 2024
Article

Read More

Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

Jordyn Sava;Susanne G. Warner, MD
October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More

FDA OKs Study of Amezalpat in Frontline Liver Cancer

FDA OKs Study of Amezalpat in Frontline Liver Cancer

Jordyn Sava
November 13th 2024
Article

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.

Read More

FDA Accepts NDA Resubmission of Rivoceranib and Camrelizumab in HCC

FDA Accepts NDA Resubmission of Rivoceranib and Camrelizumab in HCC

Jordyn Sava
October 21st 2024
Article

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic hepatocellular carcinoma is supported by the final survival analysis of CARES-310 trial.

Read More

Bringing Bispecific Antibody Therapy to Community Oncology Centers

Bringing Bispecific Antibody Therapy to Community Oncology Centers

Jordyn Sava
October 11th 2024
Article

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

Read More